Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):65-8. doi: 10.1055/s-2007-985148. Epub 2007 Oct 9.

Abstract

Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and non-diabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82+/-0.65 VS. 1.53+/-0.60 microg/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose ( R= -0.31, P<0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA (IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • Blood Pressure
  • Diabetes Mellitus, Type 2 / blood*
  • Fasting
  • Female
  • Fibroblast Growth Factors / blood*
  • Glycated Hemoglobin A / analysis
  • Humans
  • Insulin / blood
  • Insulin Resistance
  • Male
  • Middle Aged
  • Regression Analysis
  • Triglycerides / blood
  • Waist-Hip Ratio

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Insulin
  • Triglycerides
  • fibroblast growth factor 21
  • Fibroblast Growth Factors